Company intelligence / Profile preview

BioMoti Ltd

London, United Kingdomventureradar.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

Lead program BMT101 has demonstrated strong preclinical results versus standard-of-care paclitaxel, including over 10-fold increases in drug concentration in tumors, a 65-fold reduction in tumor burden, a fourfold increase in survival rates, and reduced toxicity. The company has entered into a partnership with a global pharmaceutical company to advance BMT101 into clinical phase 2a proof-of-concept studies

Therapeutic areas: Oncology
Modalities: NanomedicineDrug-loaded microparticles (specifically CD95-coated paclitaxel-loaded microparticles)
Industry: Biotech

Drug pipeline

1 asset

paclitaxel

Pre-clinical

Indications: Ovarian cancer

Partnerships

Global pharmaceutical company for development and potential licensing of BMT101 for ovarian cancer treatment; partner’s identity not publicly disclosed as of May 2022 but includes access to commercial manufacturing technology and licensing options for specific territories

Beyond the preview

Go deeper on BioMoti Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMoti Ltd.

Explore the full profile